Patient Characteristics and PSMA PET Stages
| RP | Radiotherapy | ||||
|---|---|---|---|---|---|
| Characteristic | EAU BCR low risk (n = 176) | EAU BCR high risk (n = 931) | BCP (n = 386) | EAU BCR low risk (n = 309) | EAU BCR high risk (n = 158) |
| Age (y) | 71 [9.3] | 69 [9.1] | 70 [12] | 73 [9.6] | 72 [9.1] |
| PSA ( ng/mL) | |||||
| <0.5 | 60 (34.1%) | 302 (32.4%) | 69 (17.9%) | 3 (1.0%) | 2 (1.3%) |
| ≥0.5 to <1.0 | 38 (21.6%) | 178 (19.1%) | 175 (45.3%) | 4 (1.3%) | 4 (2.5%) |
| ≥1.0 to <2.0 | 20 (11.4%) | 174 (18.7%) | 43 (11.1%) | 7 (2.3%) | 5 (3.2%) |
| ≥2.0 to <5.0 | 34 (19.3%) | 159 (17.1%) | 41 (10.6%) | 134 (43.4%) | 62 (39.2%) |
| ≥5.0 | 24 (13.6%) | 118 (12.7%) | 58 (15.0%) | 161 (52.1%) | 85 (53.8%) |
| PSA doubling time (mo) | 20 [18] | 4.2 [5.2] | 4.5 [5.8] | 8.5 [11] | 4.1 [5.7] |
| Gleason score | |||||
| 6 | 30 (17.0%) | 42 (4.5%) | 17 (4.4%) | 97 (31.4%) | 2 (1.3%) |
| 7 | 146 (83.0%) | 507 (54.5%) | 168 (43.5%) | 212 (68.6%) | 27 (17.1%) |
| 8 | — | 168 (18.0%) | 79 (20.5%) | — | 55 (34.8%) |
| 9–10 | — | 214 (23.0%) | 122 (31.6%) | — | 74 (46.8%) |
| IBF (mo) | 83 [78] | 44 [51] | 34 [55] | 88 [84] | 41 [65] |
| Adjuvant RT after RP | |||||
| Adjuvant RT | 50 (28.4%) | 368 (39.5%) | 78 (20.2%) | — | — |
| No adjuvant RT | 126 (71.6%) | 563 (60.5%) | 308 (79.8%) | 309 (100%) | 158 (100%) |
| PSMA PET stage | |||||
| T0N0M0 (no disease) | 58 (33.0%) | 275 (29.5%) | 85 (22.0%) | 20 (6.5%) | 7 (4.4%) |
| Tr/N1M0 (locoregional) | 75 (42.6%) | 314 (33.7%) | 147 (38.1%) | 176 (57.0%) | 41 (25.9%) |
| Any M1 (metastatic) | 43 (24.4%) | 342 (36.7%) | 154 (39.9%) | 113 (36.6%) | 110 (69.6%) |
| M1 group | |||||
| M1a only | 13 (7.4%) | 102 (11.0%) | 53 (13.7%) | 49 (15.9%) | 30 (19.0%) |
| Any M1b* | 19 (10.8%) | 201 (21.6%) | 88 (22.8%) | 48 (15.5%) | 65 (41.1%) |
| Any M1c | 11 (6.2%) | 39 (4.2%) | 13 (3.4%) | 16 (5.2%) | 15 (9.5%) |
| No. of M1 regions | |||||
| 0 | 133 (75.6%) | 589 (63.3%) | 232 (60.1%) | 196 (63.4%) | 48 (30.4%) |
| 1–2 | 5 (2.8%) | 55 (5.9%) | 44 (11.4%) | 11 (3.6%) | 18 (11.4%) |
| ≥3 | 38 (21.6%) | 287 (30.8%) | 110 (28.5%) | 102 (33.0%) | 92 (58.2%) |
*Not including M1c.
IBF = interval from primary therapy to biochemical failure; RT = radiotherapy.
Qualitative data are number followed by percentage in parentheses; continuous data are median followed by IQR in brackets. PSMA stages are according to PROMISE criteria (13).